Sonic Healthcare Limited (ASX:SHL) shares were priced at $18.72 on 6 October 2026, up 1.14% on the day, and are down 13.53% over the past twelve months. The diagnostics company published its FY2026 results on 20 August 2026 for the year ended 30 June 2026, with figures in Australian dollars.

Across the broader market, the S&P/ASX 200 Health Care index [XHJ] (INDEXASX: XHJ) stood at 31,982.20, up 0.63% (+200.50 points) as of 6 October, and is down 16% over the past year. Meanwhile, the S&P/ASX 200 stood at 8,735.70, up 0.57% (+49.30 points) at the same time, and is down 2.74% over the year.

Business Model and Operational Footprint

Sonic Healthcare is a medical diagnostics company operating across nine countries and 11 markets. It provides diagnostic services to more than 140 million patients per year and employs about 47,000 people. The company is also listed through an ADR programme in the United States. Its model is based on what it terms three differentiators: scale and diversification, Medical Leadership and operational excellence.

The group is headquartered in Sydney and has grown through acquisitions, with recent additions in Germany and Switzerland and the completed LADR Laboratory Group acquisition, which is progressing through integration. During the year it completed a sale and leaseback of its Brisbane hub laboratory as part of its Capital management program. Dr Jim Newcombe is the company's CEO, and the release was issued during his first nine months in the role.

Sector Dynamics

Diagnostics providers operate across multiple health systems, each with its own funding, regulation and billing arrangements. Sonic listed the factors that can affect future results as adverse decisions by governments and healthcare regulators, changes in the competitive environment and billing policies, loss of contracts, cost growth, macroeconomic and foreign exchange movements, and capital market conditions.

Industry activity noted by the company includes growth in advanced diagnostics and Investment in digital capabilities. Sonic commenced a comprehensive operating review of its United States Business and launched a program to modernise its global digital infrastructure, along with AI transformation initiatives.

FY2026 Results Update

Revenue was $10,867 million, up 13%, including organic growth of 5%. Underlying EBITDA was $1,933 million, up 11%, and statutory EBITDA was $1,882 million, up 9%. Underlying net profit was $621 million, up 17%, and statutory net profit was $608 million, up 18%. Underlying Earnings Per Share were 125.6 cents, up 14%, and statutory earnings per share were 123.0 cents, up 15%. The company said it achieved its underlying EBITDA earnings guidance.

Total dividends for the year were $1.08 per share, an increase of 1 cent. The CEO described the result as reflecting a diversified global portfolio and operational focus, and said the company realised substantial synergies from acquisitions in Germany and Switzerland. The release noted that Sonic's Financial and Operating Review Presentation and Appendix 4E were posted on its website on the day of release.

The gap between underlying and statutory figures is shown in the release as $51 million in EBITDA, $13 million in net profit, and 2.6 cents in earnings per share. A reconciliation of underlying measures to statutory results is provided in the Appendix 4E. The company also notes that underlying and constant currency measures are not prepared in accordance with IFRS and may not be comparable with similarly titled measures used by other entities.

Growth Catalysts and Critical Operating Risks

The company identified several areas it will pursue: organic growth, efficiency, innovation and disciplined capital management. Items named in the release include continued integration of LADR and realisation of synergies on schedule, growth in advanced diagnostics across multiple geographies, the digital and AI transformation program and the proceeds from the Brisbane sale and leaseback.

The operating risks listed by the company are the matters set out in its forward-looking statements: government and regulator decisions, competition and billing policy changes, lawsuits, loss of contracts, unexpected growth in costs, foreign exchange and macroeconomic conditions. The release also notes that the United States operating review is ongoing and that integration of acquisitions is still in progress. Revenue growth of 13% compares with organic growth of 5%.

Sonic's operating model is built on scale and Diversification across its markets, a Medical Leadership culture and operational excellence. The CEO said the company focuses on organic growth, efficiency, innovation and disciplined capital management, and described its aim as delivering high-value medicine at scale. Commentary in the release also thanked the company's 47,000 people for their work in caring for communities.

On capital management, the release lists the Brisbane hub laboratory sale and leaseback as completed during the year, and a one cent increase in the Dividend to a total of $1.08 per share. The company states that a fuller breakdown of its financial and operating performance is available in the FY2026 Financial and Operating Review Presentation and the Appendix 4E, which sit alongside the media release.

The Bottom Line

Sonic Healthcare reported FY2026 revenue of $10,867 million, underlying EBITDA of $1,933 million and underlying net profit of $621 million, with total dividends of $1.08 per share. Its shares are down 13.53% over the year. Organic growth was 5% against total growth of 13%, the United States business is under operating review, and integration of recent acquisitions and the digital program are continuing.